Core Principles of Vector Biodistribution and Shedding Analysis

Quantifying vector dissemination is a core component of the safety assessment for advanced therapeutics and complex biologics. A comprehensive understanding of which tissues a vector targets and how it is cleared from the body is fundamental to any successful regulatory submission. Applying proven intelligence in bioanalytical characterization for next-generation therapies results in clear, defensible data required to move forward with clinical evaluation.

Regulatory Mandates for IND-Enabling Safety Assessment

Regulatory agencies require viral shedding data to assess the potential risk of horizontal transmission to untreated individuals and to understand environmental exposure. Typically collected during IND-enabling toxicology studies, biodistribution and shedding assays form a key part of the overall risk profile for any novel gene therapy program. The analysis must be sensitive, specific, and robust enough to detect vector sequences across multiple, often challenging, biological matrices.

Quantitative Bioanalytical Platforms and Methodologies

Our laboratories are equipped to provide precise quantification of vector material to support these regulatory requirements. We tailor each analytical strategy to the specific vector and program needs.

• Quantitative Platforms: Assays are performed using qualified quantitative PCR (qPCR) and Droplet Digital PCR (ddPCR) systems for high-sensitivity detection.
• Matrix Diversity: We routinely process a wide range of sample types, including urine, saliva, feces, blood, and various tissue and swab collections.
• Vector Agnostic: Our experience covers prevalent AAV serotypes (AAV8, AAV9, engineered capsids), lentiviral vectors, and RNA payloads delivered via lipid nanoparticle (LNP) systems.
• Regulatory Compliance: All methods are developed and qualified under phase-appropriate GxP guidelines to ensure data integrity for regulatory filings.